It was a pleasure to meet with Prof. Peter Pappas (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss the interim analysis from the Phase 3 FURI study, investigating oral ibrexafungerp in the treatment of patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals.
The abstract entitled: ‘Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- What is the rationale for the use of ibrexafungerp in patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals? (0:34)
- What are the aims, and design of the FURI Phase III study? (2:05)
- What were the findings of this analysis? (3:40)
- What questions remain unanswered about the use of ibrexafungerp in this indication and what future studies are planned? (5:23)
Disclosures: Peter Pappas receives research support from Cidara, Mayne, Astellas, Gilead and Scynexis; and is also a Scientific advisor for Scynexis, Matinas and F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In Bacterial and Fungal Infections
John Walton Sanders, IDWeek 2021: Unmet Needs in the Treatment of Candida Osteoarticular Infections
It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the unmet needs in the treatment of Candida osteoarticular infections. The abstract entitled: ‘Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)’ […]
John Walton Sanders, IDWeek 2021: Subset Analysis of Phase 3 FURI Study, Investigating Candida Bone and Joint Infections
It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the a subset analysis of the Phase 3 FURI study investigating the outcomes of patients with Candida bone and joint infections when treated with ibrexafungerp. The abstract entitled: ‘Outcomes of […]
Esmita Charani: Tackling Global Antimicrobial Resistance
We caught up with touchINFECTIOUS DISEASES expert faculty member, Dr Esmita Charani (Imperial College London, London, UK), to discuss her recent research into the future research priorities to optimise antimicrobial use in humans, and what research gaps still remain. Useful resources: Research roadmap for optimising the use of antibiotics in humans Publication available here: Charani […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!